OVERVIEW

Community Practice Connections™: Saturday Night Tumor Board: Applying the Evidence to Challenging Scenarios in Patients With NSCLC & EGFR Mutations is organized by Physicians' Education Resource, LLC (PER).

Release Date: July 31, 2019
Expiration Date: July 31, 2020

Target Audience:
This educational program is directed toward primarily medical oncologists. Nurse practitioners, nurses, physician assistants, pharmacists, investigators, and other healthcare professionals interested in the treatment of lung cancer are also invited to participate.

Accreditation/Credit Designation:
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Activity Overview:
Community Practice Connections™: Saturday Night Tumor Board: Applying the Evidence to Challenging Scenarios in Patients With NSCLC & EGFR Mutations provides case-based discussion of clinical data guiding therapy for patients with non–small cell lung cancer (NSCLC) and mutations in the EGFR gene. Clinical scenarios include first-line therapy, molecular testing, management of disease progression, and treatment of patients with central nervous system (CNS) metastases. Interactive clinical vignettes are followed by short video interviews with leading experts in the management of patients with lung cancer. The video interviews address decision points in the clinical vignettes, as well as questions commonly faced in the community oncology practice setting by healthcare professionals engaged in the care of patients with EGFR mutation–positive NSCLC.

Learning Objectives:
Upon successful completion of this activity, you should be better prepared to:
• Assess the application of liquid-based and tumor-based molecular testing approaches to choose initial and subsequent lines of therapy for patients with advanced, EGFR mutation–positive NSCLC
• Evaluate clinical data on strategies for the initial management of patients with EGFR mutation–positive NSCLC
• Discuss clinical data informing the management of acquired resistance and disease progression in patients with EGFR mutation–positive NSCLC
• Describe management strategies for patients with EGFR mutation–positive NSCLC and brain metastases and/or treatment-related adverse events.